Health Canada Reviews New mRNA Flu Vaccine to Reduce Hospitalizations
Published
Health Canada is currently reviewing a new mRNA influenza vaccine that could significantly change how the country manages the flu season. The vaccine, known as mFlusiva and developed by the pharmaceutical company Moderna, aims to provide better protection against seasonal viruses than traditional options.
The vaccine has already received approval for use in the United States. Clinical data from the U.S. suggests that the mRNA technology is 27 percent more effective at preventing illness compared to standard flu shots. Health officials hope that this increased effectiveness will lead to fewer people needing hospital care during the winter months.
This development is part of a broader shift toward using mRNA technology, which became well-known during the COVID-19 pandemic, to fight other common respiratory illnesses. By using the body’s own cells to create an immune response, scientists believe this method offers a more precise way to target evolving flu strains.
Health Canada will now conduct its own rigorous evaluation of the vaccine’s safety and effectiveness before deciding if it will be available to the Canadian public. If approved, the vaccine could become an important tool for public health departments across the country to protect vulnerable populations and reduce the burden on the healthcare system.
Sources: The News International
More Canada news
- CGI Earnings Rise 9% as Investors Compare Canadian Tech Stocks
- Canada's Economy Grew in Second Quarter, But Fraser Institute Says Headlines Are Misleading
- AI and Virtual Reality Help Bring Memories Back for People with Dementia
- Canada Names First CEO for New Canada Strong Fund
- Ottawa Restores Sanctions on Iran That Were Lifted a Decade Ago
- Canada Plans Funding to Prepare for Major Earthquakes in Next Federal Budget
- Carney Issues Warning to China, According to The Globe and Mail
- Fewer Than 4,400 Second World War and Korean War Veterans Remain Alive in Canada